Study of Perforating Arteries Detection by Ultrasound Localization Microscopy (ULM) With a Commercial Conventional Ultrasound Scanner

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Transcranial Doppler ultrasonography with injection of contrast agent (intravenously to enhance the ultrasound signal) is a non-invasive technique that has been used for years to study intracranial vessels that constitute the polygon of Willis. However, this technique does not allow good visualization of small vessels, such as perforating arteries. Ultrasound localization microscopy (ULM) is based on the principle of localizing injected microbubbles in order to follow their movement to map the microvascular structure. The concentration of these microbubbles must remain low (in contrast to its classical use in Doppler ultrasound) in order to isolate and localize them. By using the same images as those performed in clinical routine by Doppler ultrasound and by processing the data offline, ULM would increase the resolution by a factor of 10 allowing potential observation of perforating arteries.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:

• Patients with ischemic stroke hospitalized in the neurology department of the Bichat Hospital in the absence of middle cerebral artery occlusion or lacunar disease.

⁃ or

• Patients followed in the neurology department of the Bichat/Lariboisière hospital with a diagnosis of Moya-Moya disease or syndrome

• Patient who has had a TST with contrast injection as part of his follow-up

• Patient who has had an MRI as part of his follow-up

• Presence of a temporal window that allows ultrasound insonification of the polygon circle of Willis.

• Age over 18 years.

• Patient not objecting to the analysis of their data

Locations
Other Locations
France
AP-HP, Bichat Hospital
RECRUITING
Paris
Contact Information
Primary
Elena MESEGUER, Doctor
elena.meseguer@aphp.fr
140257490
Backup
Jedida NDONG
140054360
Time Frame
Start Date: 2023-03-30
Estimated Completion Date: 2024-12
Participants
Target number of participants: 30
Related Therapeutic Areas
Sponsors
Collaborators: Centre National de la Recherche Scientifique, France
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov